Related Experiment Video
Updated: Jul 23, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
FGF23 and klotho at the intersection of kidney and cardiovascular disease
Daniel Edmonston1,2, Alexander Grabner1, Myles Wolf3,4
1Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Insights
Cardiovascular disease is a major risk in chronic kidney disease (CKD). In CKD, fibroblast growth factor 23 (FGF23) and low klotho contribute to heart problems, necessitating holistic treatment of mineral imbalances.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in chronic kidney disease (CKD) patients.
- CKD progression exacerbates CVD risk through CKD-specific factors like disordered mineral homeostasis.
- Fibroblast growth factor 23 (FGF23) and klotho are key regulators of mineral balance, impacting cardiovascular health.
Purpose of the Study:
- To explore the role of FGF23 and klotho in cardiovascular complications of CKD.
- To investigate the mechanisms by which FGF23 excess and klotho deficiency promote cardiac dysfunction.
- To evaluate the potential of targeting mineral homeostasis for improving cardiovascular outcomes in CKD.
Main Methods:
- Review of emerging data on FGF23 and klotho in CKD-associated cardiovascular disease.
- Analysis of the interplay between FGF23, klotho, and mineral metabolism.
- Discussion of the clinical implications for managing cardiovascular risk in CKD.
Main Results:
- Rising FGF23 and declining klotho in CKD lead to klotho-independent, detrimental cardiac effects, including left ventricular hypertrophy and heart failure.
- Soluble klotho may offer protective cardiovascular benefits through various mechanisms.
- The complex feedback loops between FGF23 and klotho make it challenging to isolate the primary driver of pathology.
Conclusions:
- Targeting disordered mineral homeostasis holistically is crucial for improving cardiovascular outcomes in CKD patients.
- Randomized trials should focus on practical interventions addressing mineral imbalances.
- Further research is needed to fully elucidate the specific roles of FGF23 and klotho in distinct cardiovascular complications of CKD.
Abstract:
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral homeostasis, amplify traditional cardiovascular risk factors. Fibroblast growth factor 23 (FGF23) regulates mineral homeostasis by activating complexes of FGF receptors and transmembrane klotho co-receptors. A soluble form of klotho also acts as a 'portable' FGF23 co-receptor in tissues that do not express klotho. In progressive CKD, rising circulating FGF23 levels in combination with decreasing kidney expression of klotho results in klotho-independent effects of FGF23 on the heart that promote left ventricular hypertrophy, heart failure, atrial fibrillation and death. Emerging data suggest that soluble klotho might mitigate some of these effects via several candidate mechanisms. More research is needed to investigate FGF23 excess and klotho deficiency in specific cardiovascular complications of CKD, but the pathophysiological primacy of FGF23 excess versus klotho deficiency might never be precisely resolved, given the entangled feedback loops that they share. Therefore, randomized trials should prioritize clinical practicality over scientific certainty by targeting disordered mineral homeostasis holistically in an effort to improve cardiovascular outcomes in patients with CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Physiology of the Genitourinary System I: Renal Blood Flow and Glomerular Filtration
Acute Kidney Injury II: Pathophysiology
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...

